Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.


OPINION STATEMENT The development of tyrosine kinase inhibitors (TKIs) dramatically changed the treatment landscape for many different cancers including chronic myeloid leukemia (CML). With the introduction of imatinib, the first TKI developed and approved to effectively treat CML, patient survival has increased dramatically and, in some cases, this fatal… (More)
DOI: 10.1007/s11936-017-0524-8

1 Figure or Table


  • Presentations referencing similar topics